TAVO-412

N/A

Report date: 2023/12/08 15:42:24

Base Information

Drug NameTAVO-412
Drug Alias NameTAVO-412
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptorVascular endothelial growth factor
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTavotek Biotherapeutics (Hong Kong) LtdTuochuang Biotechnology (Jiangsu) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTavotek BiotherapeuticsTuochuang Biotechnology (Jiangsu) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A